Who Paid My Doc
Robert Thornsberry
Sports Medicine Macon, GA Medical Doctor
NPI 1922118165 CMS profile 87564
3708 Northside Dr, Macon, GA 31210
General payments
$6,316
Research payments
$0
Ownership & investment interest
$12,819
Through program year 2025, Robert Thornsberry of Macon, GA is reported in the CMS Open Payments database as having received $6,316 across 61 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $12,819 across 6 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 47th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $275 | 3 | |
| 2024 | General | $212 | 3 | |
| 2023 | General | $1,425 | 21 | |
| 2022 | General | $324 | 2 | |
| 2021 | General | $1,313 | 7 | |
| 2020 | General | $256 | 6 | |
| 2019 | General | $2,512 | 19 | |
| 2024 | Ownership | $2,136 | 1 | |
| 2023 | Ownership | $2,136 | 1 | |
| 2022 | Ownership | $2,136 | 1 | |
| 2021 | Ownership | $2,136 | 1 | |
| 2020 | Ownership | $2,136 | 1 | |
| 2019 | Ownership | $2,136 | 1 |
Beside peers
- Robert Thornsberry
- Sports Medicine median
- Middle half of Sports Medicine
- National median
In program year 2025, general payments to Robert Thornsberry were reported at $275. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.
Show as a table
| Year | Robert Thornsberry | Sports Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,512 | $1,176 | $199–$4,249 | $163 |
| 2020 | $256 | $708 | $96–$2,890 | $114 |
| 2021 | $1,313 | $1,213 | $152–$3,994 | $132 |
| 2022 | $324 | $1,230 | $159–$3,998 | $149 |
| 2023 | $1,425 | $584 | $146–$2,836 | $160 |
| 2024 | $212 | $628 | $163–$3,168 | $164 |
| 2025 | $275 | $664 | $172–$3,055 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
1,243
Drug cost
$8,694
Branded share of claims
30.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 185 | $1,556 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 164 | $1,478 | |
| Mupirocin | Generic | 189 | $1,444 | |
| Diclofenac Sodium | Generic | 68 | $1,139 | |
| Meloxicam | Generic | 172 | $655 | |
| Ondansetron Hcl | Generic | 98 | $417 | |
| Celecoxib | Generic | 36 | $415 | |
| Tramadol Hcl | Generic | 107 | $332 | |
| Methylprednisolone | Generic | 50 | $292 | |
| Oxycodone Hcl | Generic | 29 | $197 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 73 billing codesPaid by Medicare
$290,211
Medicare patients
659
Services billed
26,250
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 34% | |
| Chronic kidney disease | 32% | |
| Ischemic heart disease | 31% | |
| Depression | 23% | |
| Atrial fibrillation | 20% | |
| Osteoporosis | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 | Office | 28 | 42 | $22,346 |
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 | Office | 12 | 992 | $13,608 |
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 | Office | 13 | 816 | $5,783 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 209 | 22,168 | $2,250 |
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 78 | 85 | $514 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 11 | 23 | $55 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
61 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Sports Medicine in Georgia
Related records
Sports Medicine in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Sports Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.